HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Smaldone, A. Search for Related Content PubMed Articles by Smaldone, A. Social Bookmarking                What's this?

Glycemic Control and Hemoglobinopathy: When A1C May Not Be Reliable

The first 300 words of the full text of this article appear below.

	Background and Clinical Problem

 
The American Diabetes Association (ADA) recommends hemoglobin A_1c (A1C) as the standard laboratory assessment of glycemic control and efficacy of treatment for patients with type 1 or type 2 diabetes.¹ Large prospective research trials in patients with type 1² and type 2 diabetes³ have demonstrated that A1C levels are directly related to risk of diabetes complications, such as retinopathy, neuropathy, and nephropathy. However, in some clinical situations, laboratory assessment using the A1C test may provide unreliable information. When an A1C result is inconsistent with a patient's clinical situation, conditions that affect red blood cell lifespan and hemoglobinopathies must be considered as possible causes^1,4 because normative values for A1C are based on individuals with a normal hematological profile.

	Hemoglobinopathy

 
Hemoglobin type is inherited. Hemoglobin A (HbA), normal adult hemoglobin, is the most common type. More than 700 forms of hemoglobinopathy or abnormal hemoglobin variants have been reported; sickle cell (HbS) is the most frequently occurring hemoglobin variant in the United States population.⁵ In sickle cell trait (HbAS), a person inherits a normal HbA gene from one parent and an HbS gene from the other.⁶ Although its prevalence is highest among African Americans (6–9%),^5,7 HbAS may also occur in those of Hispanic, Greek, Italian, and other ethnic groups. In one population, those of non–African-American ethnicity accounted for 11% of people identified as having HbAS.⁸ It is estimated that more than 2 million people in the United States have HbAS.⁹ Because of its prevalence and wide ethnic variation, testing for sickle cell and other selected hemoglobinopathies is routinely performed as part of newborn screening programs in the United States.

	Hemoglobinopathy and interference with A1C assessment

 
A1C represents the main fraction of hemoglobin bound to glucose (glycohemoglobin) and is normally present at low levels in red blood cells.¹⁰ In patients with diabetes having normal hemoglobin, A1C values strongly correlate with blood . . . [Full Text of this Article]

	Case Study

 

	Clinical Question

 

	PICO Format

 

	Search Strategy

 

	Results and Critical Appraisal: Description of studies

 

	Hemoglobinopathy in patients with diabetes

 

	Variation by laboratory method

 

	Assessment of glycemic control using fructosamine

 

	Summary and Evidence Grading System for Clinical Practice Recommendations

 

	Case Study Revisited

 

	Clinical Question Revisited

 

	Implication for Practice

 

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?